T0	Participants 227 267	hepatocellular carcinoma (HCC) patients.
T1	Participants 370 383	HCC patients.
T2	Participants 620 700	85 patients enrolled into this study, 79 cases (38 in group A and 41 in group B)
T3	Participants 706 742	pathologically confirmed to have HCC
T4	Participants 1746 1771	early-stage HCC patients.